Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene addiction. This study assesses KI plasma levels and their clinical relevance in patients chronically exposed to KIs. Plasma samples were collected...
Saved in:
Published in | Cancers Vol. 12; no. 12; p. 3758 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
14.12.2020
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene addiction. This study assesses KI plasma levels and their clinical relevance in patients chronically exposed to KIs. Plasma samples were collected in NSCLC patients receiving erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib) for at least three months between November 2013 and February 2019 in a single institution. KI drug concentrations were measured by ultra-performance liquid chromatography coupled with tandem mass spectrometry and compared to published data defining optimal plasma concentration. The main outcome was the rate of samples with suboptimal KI plasma concentrations. Secondary outcomes included its impact on
mutation emergence in patients receiving a first-generation epidermal growth factor receptor (EGFR) KI. Fifty-one samples were available from 41 patients with advanced NSCLC harboring driver genetic alterations, including
, v-Raf murine sarcoma viral oncogene homolog B (
), anaplastic lymphoma kinase (
) or ROS proto-oncogene 1 (
), and who had an available evaluation of chronic KI plasma exposure. Suboptimal plasma concentrations were observed in 51% (26/51) of cases. In
-mutant cases failing first-generation KIs,
exon 20 p.T790M mutation emergence was detected in 31% (4/13) of samples in optimal vs. none in suboptimal concentration (0/5). Suboptimal plasma concentrations of KIs are frequent in advanced NSCLC patients treated with a KI for at least three months and might contribute to treatment failure. |
---|---|
AbstractList | Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene addiction. This study assesses KI plasma levels and their clinical relevance in patients chronically exposed to KIs. Plasma samples were collected in NSCLC patients receiving erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib) for at least three months between November 2013 and February 2019 in a single institution. KI drug concentrations were measured by ultra-performance liquid chromatography coupled with tandem mass spectrometry and compared to published data defining optimal plasma concentration. The main outcome was the rate of samples with suboptimal KI plasma concentrations. Secondary outcomes included its impact on
mutation emergence in patients receiving a first-generation epidermal growth factor receptor (EGFR) KI. Fifty-one samples were available from 41 patients with advanced NSCLC harboring driver genetic alterations, including
, v-Raf murine sarcoma viral oncogene homolog B (
), anaplastic lymphoma kinase (
) or ROS proto-oncogene 1 (
), and who had an available evaluation of chronic KI plasma exposure. Suboptimal plasma concentrations were observed in 51% (26/51) of cases. In
-mutant cases failing first-generation KIs,
exon 20 p.T790M mutation emergence was detected in 31% (4/13) of samples in optimal vs. none in suboptimal concentration (0/5). Suboptimal plasma concentrations of KIs are frequent in advanced NSCLC patients treated with a KI for at least three months and might contribute to treatment failure. Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene addiction. This study assesses KI plasma levels and their clinical relevance in patients chronically exposed to KIs. Plasma samples were collected in NSCLC patients receiving erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib) for at least three months between November 2013 and February 2019 in a single institution. KI drug concentrations were measured by ultra-performance liquid chromatography coupled with tandem mass spectrometry and compared to published data defining optimal plasma concentration. The main outcome was the rate of samples with suboptimal KI plasma concentrations. Secondary outcomes included its impact on T790M mutation emergence in patients receiving a first-generation epidermal growth factor receptor (EGFR) KI. Fifty-one samples were available from 41 patients with advanced NSCLC harboring driver genetic alterations, including EGFR, v-Raf murine sarcoma viral oncogene homolog B (BRAF), anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1), and who had an available evaluation of chronic KI plasma exposure. Suboptimal plasma concentrations were observed in 51% (26/51) of cases. In EGFR-mutant cases failing first-generation KIs, EGFR exon 20 p.T790M mutation emergence was detected in 31% (4/13) of samples in optimal vs. none in suboptimal concentration (0/5). Suboptimal plasma concentrations of KIs are frequent in advanced NSCLC patients treated with a KI for at least three months and might contribute to treatment failure. |
Author | Lacroix, Ludovic Auclin, Edouard Lavaud, Pernelle Gougis, Paul Mir, Olivier Delahousse, Julia Gazzah, Anas Rouleau, Etienne Planchard, David Combarel, David Paci, Angelo Massard, Christophe Geraud, Arthur Mezquita, Laura Vasseur, Damien Besse, Benjamin Adam, Julien Caramella, Caroline Jovelet, Cécile Naltet, Charles |
AuthorAffiliation | 10 Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France; cecile.jovelet@gustaveroussy.fr (C.J.); ludovic.lacroix@gustaveroussy.fr (L.L.); etienne.rouleau@gustaveroussy.fr (E.R.); damien.vasseur@gustaveroussy.fr (D.V.) 8 CLIP2 Galilée, Regional Pharmacovigilance Center, Pitié-Salpêtrière Hospital, INSERM, CIC-1421, Sorbonne University, 75013 Paris, France 11 Department of Medical Imaging, Gustave Roussy, 94805 Villejuif, France; caroline.caramella@gustaveroussy.fr 12 Pathology Department, Gustave Roussy, 94805 Villejuif, France; julien.adam@gustaveroussy.fr 13 Department of Ambulatory Cancer Care, Gustave Roussy, 94805 Villejuif, France; olivier.mir@gustaveroussy.fr 5 Pharmacology Department, Gustave Roussy, 94805 Villejuif, France; david.combarel@gustaveroussy.fr (D.C.); julia.delahousse@gustaveroussy.fr (J.D.); angelo.paci@gustaveroussy.fr (A.P.) 1 Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France; arthur.geraud@gustaveroussy.fr (A.G.); lmez |
AuthorAffiliation_xml | – name: 10 Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France; cecile.jovelet@gustaveroussy.fr (C.J.); ludovic.lacroix@gustaveroussy.fr (L.L.); etienne.rouleau@gustaveroussy.fr (E.R.); damien.vasseur@gustaveroussy.fr (D.V.) – name: 8 CLIP2 Galilée, Regional Pharmacovigilance Center, Pitié-Salpêtrière Hospital, INSERM, CIC-1421, Sorbonne University, 75013 Paris, France – name: 5 Pharmacology Department, Gustave Roussy, 94805 Villejuif, France; david.combarel@gustaveroussy.fr (D.C.); julia.delahousse@gustaveroussy.fr (J.D.); angelo.paci@gustaveroussy.fr (A.P.) – name: 13 Department of Ambulatory Cancer Care, Gustave Roussy, 94805 Villejuif, France; olivier.mir@gustaveroussy.fr – name: 7 Department of Pharmacology and Clinical Investigation Center, Pitié-Salpêtrière Hospital, INSERM, CIC-1421, Sorbonne University, 75013 Paris, France; paul.gougis@aphp.fr – name: 4 Department of Medical and Digestive Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France; edouard.auclin@aphp.fr – name: 2 Early Drug Development Department (DITEP), Gustave Roussy, 94805 Villejuif, France; christophe.massard@gustaveroussy.fr (C.M.); anas.gazzah@gustaveroussy.fr (A.G.) – name: 6 Faculty of Pharmacy, Paris-Saclay University, 92296 Chatenay-Malabry, France – name: 9 Paris-Saclay University, Cancer Campus Gustave Roussy, Gustave Roussy, 94805 Villejuif, France – name: 3 Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain – name: 1 Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France; arthur.geraud@gustaveroussy.fr (A.G.); lmezquitap@clinic.cat (L.M.); charles.naltet@gustaveroussy.fr (C.N.); pernelle.lavaud@gustaveroussy.fr (P.L.); david.planchard@gustaveroussy.fr (D.P.) – name: 11 Department of Medical Imaging, Gustave Roussy, 94805 Villejuif, France; caroline.caramella@gustaveroussy.fr – name: 12 Pathology Department, Gustave Roussy, 94805 Villejuif, France; julien.adam@gustaveroussy.fr |
Author_xml | – sequence: 1 givenname: Arthur orcidid: 0000-0001-9902-0877 surname: Geraud fullname: Geraud, Arthur organization: Early Drug Development Department (DITEP), Gustave Roussy, 94805 Villejuif, France – sequence: 2 givenname: Laura surname: Mezquita fullname: Mezquita, Laura organization: Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Medical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain – sequence: 3 givenname: Edouard surname: Auclin fullname: Auclin, Edouard organization: Department of Medical and Digestive Oncology, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, 75015 Paris, France – sequence: 4 givenname: David surname: Combarel fullname: Combarel, David organization: Faculty of Pharmacy, Paris-Saclay University, 92296 Chatenay-Malabry, France – sequence: 5 givenname: Julia surname: Delahousse fullname: Delahousse, Julia organization: Pharmacology Department, Gustave Roussy, 94805 Villejuif, France – sequence: 6 givenname: Paul orcidid: 0000-0003-3064-7043 surname: Gougis fullname: Gougis, Paul organization: CLIP2 Galilée, Regional Pharmacovigilance Center, Pitié-Salpêtrière Hospital, INSERM, CIC-1421, Sorbonne University, 75013 Paris, France – sequence: 7 givenname: Christophe surname: Massard fullname: Massard, Christophe organization: Paris-Saclay University, Cancer Campus Gustave Roussy, Gustave Roussy, 94805 Villejuif, France – sequence: 8 givenname: Cécile surname: Jovelet fullname: Jovelet, Cécile organization: Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France – sequence: 9 givenname: Caroline surname: Caramella fullname: Caramella, Caroline organization: Department of Medical Imaging, Gustave Roussy, 94805 Villejuif, France – sequence: 10 givenname: Julien surname: Adam fullname: Adam, Julien organization: Pathology Department, Gustave Roussy, 94805 Villejuif, France – sequence: 11 givenname: Charles surname: Naltet fullname: Naltet, Charles organization: Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France – sequence: 12 givenname: Pernelle surname: Lavaud fullname: Lavaud, Pernelle organization: Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France – sequence: 13 givenname: Anas surname: Gazzah fullname: Gazzah, Anas organization: Early Drug Development Department (DITEP), Gustave Roussy, 94805 Villejuif, France – sequence: 14 givenname: Ludovic surname: Lacroix fullname: Lacroix, Ludovic organization: Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France – sequence: 15 givenname: Etienne surname: Rouleau fullname: Rouleau, Etienne organization: Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France – sequence: 16 givenname: Damien surname: Vasseur fullname: Vasseur, Damien organization: Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France – sequence: 17 givenname: Olivier orcidid: 0000-0002-6761-4002 surname: Mir fullname: Mir, Olivier organization: Department of Ambulatory Cancer Care, Gustave Roussy, 94805 Villejuif, France – sequence: 18 givenname: David surname: Planchard fullname: Planchard, David organization: Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France – sequence: 19 givenname: Angelo surname: Paci fullname: Paci, Angelo organization: Faculty of Pharmacy, Paris-Saclay University, 92296 Chatenay-Malabry, France – sequence: 20 givenname: Benjamin surname: Besse fullname: Besse, Benjamin organization: Paris-Saclay University, Cancer Campus Gustave Roussy, Gustave Roussy, 94805 Villejuif, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33327482$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkstv1DAQxi1UREvpmRuyxIVLqF_xxBekKiqwYkUrAWfLcZxdrxJ7sRMe_z1ut1RtffDzN59mxt9LdBRicAi9puQ954qcWxOsS5kyyjjUzTN0wgiwSkoljh7sj9FZzjtSBucUJLxAx5xzBqJhJ2jXblMM3uLr0eTJ4Ms_-5iX5PAc8RcfTHZ4Fba-83NMGfuAr83sXZgz_u3nLb4KNm5ccNVF33s7ux5_jaH6NplxxK0r03oJG9zeJvoKPR_MmN3Z3XqKfny8_N5-rtZXn1btxbqyooG56kDIBuqe9xZsRykQqWSjekMHKbkUwkjX9Uo4Kxg1xNQObA2NUQMAiGHgp2h10O2j2el98pNJf3U0Xt9exLTRJs3ejk5LS4QENVDBjKA1b0C5ARTnfTlIy4vWh4PWfukm19tSeTLjI9HHL8Fv9Sb-0gBSKEWLwLs7gRR_Li7PevLZls6Y4OKSNRNAFCGUqYK-fYLu4pJCadUNVX6ZQgOFOj9QNsWckxvuk6FE39hCP7FFiXjzsIZ7_r8J-D9Hw7U7 |
CitedBy_id | crossref_primary_10_3390_pharmaceutics14091844 crossref_primary_10_3389_fcell_2022_753957 crossref_primary_10_1016_S1470_2045_21_00467_8 crossref_primary_10_1007_s40278_021_94640_x |
Cites_doi | 10.1056/NEJMoa1713137 10.1002/cpt.787 10.1007/s40262-016-0503-3 10.1007/s00228-019-02704-2 10.1158/1078-0432.CCR-05-2235 10.1097/FTD.0b013e3181b2c8cf 10.1016/S1470-2045(13)70579-5 10.1016/j.jpba.2018.05.052 10.1200/JCO.2017.76.7293 10.1007/s40262-014-0137-2 10.1136/esmoopen-2018-000445 10.1200/JCO.19.01758 10.1007/s10637-011-9764-8 10.1200/JCO.2009.26.3087 10.1182/blood.V126.23.133.133 10.1016/j.ejca.2014.04.015 10.1097/FTD.0000000000000004 10.1055/s-0043-116492 10.1016/j.critrevonc.2019.06.006 10.1634/theoncologist.2014-0156 10.1158/1078-0432.CCR-18-2748 10.1158/1078-0432.CCR-12-2246 |
ContentType | Journal Article |
Copyright | 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 by the authors. 2020 |
Copyright_xml | – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 by the authors. 2020 |
DBID | NPM AAYXX CITATION 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.3390/cancers12123758 |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Biological Science Collection Research Library Biological Science Database Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2072-6694 |
ExternalDocumentID | oai_doaj_org_article_6c04679f142a4153879ef7933d1536c3 10_3390_cancers12123758 33327482 |
Genre | Journal Article |
GroupedDBID | --- 3V. 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ ABDBF ABUWG ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU DIK DWQXO E3Z EBD ESX GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HYE IAO IHR KQ8 LK8 M2O M48 M7P MODMG M~E NPM OK1 P6G PGMZT PIMPY PQQKQ PROAC RIG RPM TUS AAYXX AFPKN CITATION 7T5 7TO 7XB 8FK H94 MBDVC PQEST PQUKI PRINS Q9U 7X8 ITC 5PM |
ID | FETCH-LOGICAL-c487t-b746875d3dc7cb117069689da1f663644a6ebd94ec421a0a5e7c578a9f7774ff3 |
IEDL.DBID | RPM |
ISSN | 2072-6694 |
IngestDate | Fri Oct 04 12:58:07 EDT 2024 Tue Sep 17 21:17:42 EDT 2024 Fri Aug 16 07:41:35 EDT 2024 Thu Oct 10 19:34:45 EDT 2024 Thu Sep 26 21:24:30 EDT 2024 Wed Oct 16 00:44:51 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | non-small cell lung cancer chronic plasmatic exposure oncogene addiction kinase inhibitors resistance mutation |
Language | English |
License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c487t-b746875d3dc7cb117069689da1f663644a6ebd94ec421a0a5e7c578a9f7774ff3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6761-4002 0000-0003-3064-7043 0000-0001-9902-0877 0000-0001-8787-1498 0000-0003-2535-1010 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764991/ |
PMID | 33327482 |
PQID | 2471211787 |
PQPubID | 2032421 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6c04679f142a4153879ef7933d1536c3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7764991 proquest_miscellaneous_2470900129 proquest_journals_2471211787 crossref_primary_10_3390_cancers12123758 pubmed_primary_33327482 |
PublicationCentury | 2000 |
PublicationDate | 20201214 |
PublicationDateYYYYMMDD | 2020-12-14 |
PublicationDate_xml | – month: 12 year: 2020 text: 20201214 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Cancers |
PublicationTitleAlternate | Cancers (Basel) |
PublicationYear | 2020 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Mathijssen (ref_7) 2014; 15 Jansman (ref_17) 2017; 56 Verheijen (ref_3) 2017; 102 Gougis (ref_19) 2019; 141 Rousselot (ref_12) 2015; 126 Reis (ref_14) 2018; 158 Hiemke (ref_11) 2018; 51 Widmer (ref_13) 2014; 50 Marin (ref_9) 2010; 28 Yu (ref_20) 2013; 19 Soria (ref_2) 2018; 378 Mir (ref_8) 2019; 25 Arrondeau (ref_10) 2011; 30 Doherty (ref_22) 2018; 3 Hamilton (ref_6) 2006; 12 Pistilli (ref_18) 2020; 38 Yu (ref_4) 2014; 53 Kalemkerian (ref_1) 2018; 36 Groenland (ref_5) 2019; 75 Wang (ref_15) 2009; 31 Huillard (ref_21) 2014; 19 Lankheet (ref_16) 2014; 36 |
References_xml | – volume: 378 start-page: 113 year: 2018 ident: ref_2 article-title: Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1713137 contributor: fullname: Soria – volume: 102 start-page: 765 year: 2017 ident: ref_3 article-title: Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology publication-title: Clin. Pharmacol. Ther. doi: 10.1002/cpt.787 contributor: fullname: Verheijen – volume: 56 start-page: 683 year: 2017 ident: ref_17 article-title: Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-016-0503-3 contributor: fullname: Jansman – volume: 75 start-page: 1309 year: 2019 ident: ref_5 article-title: Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/s00228-019-02704-2 contributor: fullname: Groenland – volume: 12 start-page: 2166 year: 2006 ident: ref_6 article-title: Effects of Smoking on the Pharmacokinetics of Erlotinib publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-2235 contributor: fullname: Hamilton – volume: 31 start-page: 579 year: 2009 ident: ref_15 article-title: A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0b013e3181b2c8cf contributor: fullname: Wang – volume: 15 start-page: e315 year: 2014 ident: ref_7 article-title: Drug–drug interactions with tyrosine-kinase inhibitors: A clinical perspective publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(13)70579-5 contributor: fullname: Mathijssen – volume: 158 start-page: 174 year: 2018 ident: ref_14 article-title: Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2018.05.052 contributor: fullname: Reis – volume: 36 start-page: 911 year: 2018 ident: ref_1 article-title: Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.76.7293 contributor: fullname: Kalemkerian – volume: 53 start-page: 305 year: 2014 ident: ref_4 article-title: Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-014-0137-2 contributor: fullname: Yu – volume: 3 start-page: e000445 year: 2018 ident: ref_22 article-title: Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma publication-title: ESMO Open doi: 10.1136/esmoopen-2018-000445 contributor: fullname: Doherty – volume: 38 start-page: 2762 year: 2020 ident: ref_18 article-title: Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.01758 contributor: fullname: Pistilli – volume: 30 start-page: 2046 year: 2011 ident: ref_10 article-title: Sorafenib exposure decreases over time in patients with hepatocellular carcinoma publication-title: Investig. New Drugs doi: 10.1007/s10637-011-9764-8 contributor: fullname: Arrondeau – volume: 28 start-page: 2381 year: 2010 ident: ref_9 article-title: Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.26.3087 contributor: fullname: Marin – volume: 126 start-page: 133 year: 2015 ident: ref_12 article-title: Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study publication-title: Blood doi: 10.1182/blood.V126.23.133.133 contributor: fullname: Rousselot – volume: 50 start-page: 2020 year: 2014 ident: ref_13 article-title: Review of therapeutic drug monitoring of anticancer drugs part two–Targeted therapies publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2014.04.015 contributor: fullname: Widmer – volume: 36 start-page: 326 year: 2014 ident: ref_16 article-title: Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0000000000000004 contributor: fullname: Lankheet – volume: 51 start-page: 9 year: 2018 ident: ref_11 article-title: Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 publication-title: Pharmacopsychiatry doi: 10.1055/s-0043-116492 contributor: fullname: Hiemke – volume: 141 start-page: 112 year: 2019 ident: ref_19 article-title: Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use publication-title: Crit. Rev. Oncol. doi: 10.1016/j.critrevonc.2019.06.006 contributor: fullname: Gougis – volume: 19 start-page: e3 year: 2014 ident: ref_21 article-title: Sorafenib in Thyroid Cancer Patients: Learning From Toxicity publication-title: Oncol. doi: 10.1634/theoncologist.2014-0156 contributor: fullname: Huillard – volume: 25 start-page: 1479 year: 2019 ident: ref_8 article-title: Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-2748 contributor: fullname: Mir – volume: 19 start-page: 2240 year: 2013 ident: ref_20 article-title: Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2246 contributor: fullname: Yu |
SSID | ssj0000331767 |
Score | 2.2918139 |
Snippet | Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 3758 |
SubjectTerms | Addictions Cancer therapies Chromatography chronic plasmatic exposure Drug dosages Epidermal growth factor Epidermal growth factor receptors Gefitinib kinase inhibitors Kinases Liquid chromatography Lung cancer Mass spectroscopy Mutation non-small cell lung cancer Non-small cell lung carcinoma oncogene addiction Oncogenes Patients Pharmacokinetics Plasma Plasma levels Population Protein-tyrosine kinase Raf protein resistance mutation Sarcoma Small cell lung carcinoma |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS-UwFD6Ii8GN6PiqjyEDLtwEb5o2sUu9KDozPkAFdyVJE6xoKt4r-PM9p62Xe0WYjZtCm1CSc5Kc70vCdwB2lVGp8MpxoemYUR1YbgtnOAZ3l0tbkaY43ba4UKe32Z-7_G4q1RfdCevkgTvD7SuHDE4XQWSpyWh66sIHHFSywhflOp1PkU-RqXYNlhgXle60fCTy-n1HRnwZCVqqNSV4nwpDrVr_VxDz803JqdBzsgSLPWZkh11bl2HOx5_w47w_FV-Bh17hll0hFH4y7PjtuaGNPzZu2N86YpxiZ_G-tjVl1mF1ZFedmOqI0S4su4yuwWHk-WGFf0QEyi6ayK-fzOMjG3p8_MMFgQ3bnq3C7cnxzfCU9zkUuEMqMuZWo_11XsnKaWcpzQyp4RSVEQGxBoIho7ytisy7LBVmYHKvHU5iUwSNwDAEuQbzsYl-A5hBMmsHQTj0YOaMLeiENZNWB1khyAwJ7H2YtHzupDJKpBhk_fKT9RM4IpNPqpHGdfsBPV_2ni__5_kEtj8cVvYTb1SmGGxxPOAylMDvSTFOGToHMdE3r22dQdHuwCWw3vl30hIpJfL0gzQBPeP5mabOlsT6vpXl1lohfRSb39G3LVhIidiLlItsG-bHL69-B9HP2P5qB_o70F8BYw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBddC2MvZeu-vHVDgz3sRTSyFKl-Gm1I6b6ysK3QN6PP1aWVsySF_fm7s5WsKWMvBlvGyHfS3e93J-4IeauMKnlQjnGNaUZ1aJmtnGHg3N1QWI81xfG0xUSdnsmP58PzHHBb5GOVK5vYGWrfOoyRH5RgRYGswPp6P_vFsGsUZldzC417ZKfkEtO0O8fjyfTbOsoyEOAfle5r-gjg9wcOhTlfcDTZGhu933JHXdX-f0HNuycmb7mgk4dkN2NHetQr-xHZCmmP3P-Ss-OPyWWudEunAImvDR3_nrUYAKTLln5qEvgr-iFdNLbBDju0SXTaF1VdUIzG0q_JtbCcAjvy8EVAonTSJvb92lxd0VGAy2cwDHTU_dkTcnYy_jE6ZbmXAnNASZbMatCDHnrhnXYW281gVZzKGx4BcwAoMipYX8ngZMnNwAyDdrCZTRU1AMQYxVOyndoUnhNqgNTaQeQONCmdsRVmWqWwOgoPYDMW5N1KpPWsL5lRA9VA6dd3pF-QYxT5-jWsdd09aOc_67x1auWAw-sqclkaiQZaVyGCWREebpQTBdlfKazOG3BR_10uBXmzHoatg_kQk0J7070zqLpIXEGe9fpdz0QIAXz9sCyI3tD8xlQ3R1Jz0ZXn1loBjeQv_j-tl-RBidSdl4zLfbK9nN-EV4BvlvZ1XsR_AP-X-94 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB1BkRAXBOUrUCojceBiWMdeuzkgVFatykdLJVipt8h27DZo65TdrVT-PTNJdtut9sglUuIkSmbsmfds6w3AW211LoL2XBhaZtQ7jrvCW47J3Q-lq0hTnHZbHOmDsfp6Mjy5LgfUG3C2ltpRPanxdPL-6s_fTzjgPxLjRMr-wZN9pjNBURjh7124lyupqLsf9li_DcsSU6U2nbzPuudWMlMr4L8Odd7ePHkjG-0_goc9jGS7nd8fw52QNuH-Yb9Q_gR-96K37BjR8blle1cXDc0FsnnDvtUJUxf7ks5qV1OxHVYndtzpq84YTcyyH8k32LMC363wjQhK2VGT-M9zO5mwUcDDd4wRbNT-2VMY7-_9Gh3wvqwC98hO5twZdIkZVrLyxjuqPEMCOUVlRUT4gfjI6uCqQgWvcmEHdhiMx3Fti2gQK8Yon8FGalJ4Acwiv3WDKDw6VXnrClp0VdKZKCvEnTGDdwuTlhedekaJrIOsX96yfgafyeTL20j2ur3QTE_LfhSV2iOdN0UUKreKYrUpQsQIIys80V5msLVwWLnoSmWO-RdpLkamDN4sm3EU0dKITaG5bO8ZFO2kXAbPO_8uv0RKidR9J8_ArHh-5VNXW1J91ip1G6ORUYqX_-PfXsGDnLi-yLlQW7Axn16G1wiI5m677ej_AI1cCp0 priority: 102 providerName: Scholars Portal |
Title | Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33327482 https://www.proquest.com/docview/2471211787 https://search.proquest.com/docview/2470900129 https://pubmed.ncbi.nlm.nih.gov/PMC7764991 https://doaj.org/article/6c04679f142a4153879ef7933d1536c3 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFD60HZS-jN3nrQsa7GEvbiLLluLHNqTrLsnCtkLejCRLrUcihySF_fwdyXZoyp72IvAVWUc65_uk408AH7jkCTVcx1T4ZUY-VLHKtYwxuOuMqdJrivtsiym_uk6_zLP5AWTdvzAhaV-r6swtlmeuug25laul7nd5Yv3ZZCQER6BO-4dwKBi7R9GD-2UYErloZHwYUvq-9u233lDvpREen8AxYwzZ2DDZC0ZBs_9fQPNhvuS9AHT5BB63yJGcNzV8CgfGPYPjSbs2_hx-tzq3ZIaAeCnJ-M-q9tN_ZFuTr5XDaEU-u9tKVX5_HVI5MmskVTfEz8WS707X2JlMfF7iGxGHkmnt4p9LuViQkcHiG7oFMgof-QKuL8e_Rldxu5NCrJGQbGMl0AoiK1mphVZ-sxmviZOXklpEHAiJJDeqzFOj04TKgcyM0DiUZW4FwkNr2Us4crUzr4FIpLRqYKlGO6Zaqtyvs6ZMCctKhJo2go9dkxarRjCjQKLhDVE8MEQEF77Jd7d5petwol7fFK29C66RwYvc0jSRqXfPIjcWnQor8YBrFsFpZ7CiHX6bIsGQi8wWnVEE73eXceD41RDpTH0X7hnkYR4ugleNfXc16fpHBGLP8ntV3b-CfTWIc7d9881_P_kWThLP6WkS0_QUjrbrO_MOgc9W9eDRxXg6-9ELEwdYfppTLCfpsBeGwF9zoAf2 |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,21416,24346,27955,27956,33777,33778,43838,53825,53827,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwED5BJwEviJ8jMMBIPPBirY5Tu3lCW9WpY12pYJP2FtmOw4o2p7SdxJ_PXeKWdUK8REocRc6dfffdnfUdwEdlVCq8clxoKjOqvuU2d4ajc3c9aUviFKfTFhM1Os--XPQuYsJtGY9Vrm1iY6jL2lGOfD9FK4rBCq6vz_NfnLpGUXU1ttC4DztEudnvwM7hcDL9tsmydCX6R6VbTh-J8f2-I2EuloJMtqZG77fcUcPa_y-oeffE5C0XdPQEHkfsyA5aZT-Fez48gwensTr-HH5Gpls2RUh8bdjw97ymBCBb1exkFtBfseNwObMz6rDDZoFNW1LVJaNsLPsaXI3LyfODEr-ISJRN6sC_X5urKzbweBmjYWCD5s9ewPnR8Gww4rGXAncYkqy41agH3Stl6bSz1G6GWHHy0ogKMQeCIqO8LfPMuywVpmt6XjvczCavNALEqpIvoRPq4F8BMyhp262EQ01mzticKq2ZtLqSJYLNKoFPa5EW85Yyo8BQg6Rf3JF-Aock8s1rxHXdPKgXP4q4dQrlMIbXeSWy1GRkoHXuKzQrssQb5WQCe2uFFXEDLou_yyWBD5th3DpUDzHB1zfNO928ycQlsNvqdzMTKSXG6_00Ab2l-a2pbo-E2WVDz621wjBSvP7_tN7Dw9HZ6bgYH09O3sCjlMJ4kXKR7UFntbjxbxHrrOy7uKD_ABCM_tQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkyZeEN9kDDASD7xYrWPXXp7QVlptbJQKmLS3yHZsFrQ5XdtJ_PncJW5ZJ8RLpMRR5Nyd7-53d7oj5L0yKudeOcY1phnVvmW2cIaBcXcDYSvsKY7VFhN1dCY_nw_OU_3TIpVVrnRiq6irxmGMvJeDFgWwAvLVC6ksYvpp_HF2zXCCFGZa0ziN-2RbSzUAILZ9OJpMv60jLn0BtlLprr-PAKzfc0jY-YKj-tY49P2WaWo7-P_L7bxbPXnLHI0fkYfJj6QHHeMfk3s-PiE7X1Km_Cn5lbre0im4x1eGjn7PGgwG0mVDT-oItosex4va1jhth9aRTrsGqwuKkVn6NboGRMuzgwq-CF4pnTSRfb8yl5d06OFyCkqCDts_e0bOxqMfwyOW5iowB_BkySzQB2BKJSqnncXRM9ghp6gMD-B_gINklLdVIb2TOTd9M_DawcE2RdDgLIYgnpOt2ET_klADANf2A3fAVemMLTDrKoXVQVTgeIaMfFiRtJx17TNKgB1I_fIO9TNyiCRfv4Z9r9sHzfxnmY5RqRzgeV0ELnMjUVnrwgdQMaKCG-VERvZWDCvTYVyUf0UnI-_Wy3CMMDdiom9u2nf6RRuVy8iLjr_rnQghALvv5xnRG5zf2OrmSqwv2lbdWiuAlHz3_9t6S3ZAlsvT48nJK_IgR0TPc8blHtlazm_8a3B7lvZNkuc_5ZADFw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chronic+Plasma+Exposure+to+Kinase+Inhibitors+in+Patients+with+Oncogene-Addicted+Non-Small+Cell+Lung+Cancer&rft.jtitle=Cancers&rft.au=Arthur+Geraud&rft.au=Laura+Mezquita&rft.au=Edouard+Auclin&rft.au=David+Combarel&rft.date=2020-12-14&rft.pub=MDPI+AG&rft.eissn=2072-6694&rft.volume=12&rft.issue=12&rft.spage=3758&rft_id=info:doi/10.3390%2Fcancers12123758&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6c04679f142a4153879ef7933d1536c3 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |